IsoRay

Radiotherapy Market Worth $8.8 Billion | MarketsandMarkets

Retrieved on: 
Friday, November 10, 2023
EBRT, Research, Radiation, Prevalence, Incidence, Hitachi, Risk, Hospital, IsoRay, Patient, Radiation exposure, Brachytherapy, Medical tourism, Cancer, Pulse, R, Growth, MRI, Government, GE HealthCare, Medical imaging, Retail, Marketing

The external beam radiotherapy segment, by procedure, is expected to register the largest market share of the global radiotherapy systems market in 2023.

Key Points: 
  • The external beam radiotherapy segment, by procedure, is expected to register the largest market share of the global radiotherapy systems market in 2023.
  • Based on procedure, the radiotherapy market is segmented into external beam radiotherapy, internal beam radiotherapy/brachytherapy, and systemic radiotherapy.
  • Additionally rising medical tourism and entry of major market players in the Asia Pacific countries are likely to support the radiotherapy market growth in APAC.
  • ·  Newer and improved representation of financial information: In the latest edition of the Radiotherapy  market report, the market ranking analysis of top players in the Radiotherapy  market has been provided for base year (2022) by extensively studying the financial revenues generated by the major players operating in the Radiotherapy  market.

Isoray Inc. and Viewpoint Molecular Targeting Inc. Announce Name Change to Perspective Therapeutics Inc.

Retrieved on: 
Tuesday, February 7, 2023
Oppenheimer Holdings, Certificate of incorporation, NYSE American, NYSE, LLP, ISR, IsoRay, Radiopharmaceutical, Radiation, Therapy, 3D printing

RICHLAND, Wash. and CORALVILLE, Iowa, Feb. 07, 2023 (GLOBE NEWSWIRE) -- Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in seed brachytherapy and its newly merged partner Viewpoint Molecular Targeting, Inc., today announced that they are now doing business as Perspective Therapeutics, Inc., along with a new brand identity effective immediately. Isoray, Inc. will change its name to Perspective Therapeutics, Inc. by filing an amendment to its Certificate of Incorporation as soon as possible.

Key Points: 
  • Isoray, Inc. will change its name to Perspective Therapeutics, Inc. by filing an amendment to its Certificate of Incorporation as soon as possible.
  • New NYSE American stock ticker symbol to be CATX, effective February 21, 2023
    “We believe that Perspective Therapeutics truly reflects our potential to transform the field of precision oncology medicine and the outcome of early-stage cancers through the advancement of radiopharmaceuticals,” said Perspective Therapeutics, Inc. CEO Thijs Spoor.
  • Oppenheimer & Co. acted as Isoray’s financial advisor for the merger transaction and Gallagher & Kennedy, P.A.
  • Sichenzia Ross Ference, LLP acted as Viewpoint’s legal counsel.

Isoray Announces Results of Fiscal 2023 Annual Meeting of Stockholders

Retrieved on: 
Monday, January 30, 2023
NYSE, Shareholder, ISR, Common stock, IsoRay, Coffee, Security (finance), Holding company

RICHLAND, Wash., Jan. 30, 2023 (GLOBE NEWSWIRE) -- Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in seed brachytherapy powering expanding treatment options throughout the body, today announced the results of its adjourned Fiscal 2023 Annual Meeting of Stockholders which was held on January 27, 2023.

Key Points: 
  • RICHLAND, Wash., Jan. 30, 2023 (GLOBE NEWSWIRE) -- Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in seed brachytherapy powering expanding treatment options throughout the body, today announced the results of its adjourned Fiscal 2023 Annual Meeting of Stockholders which was held on January 27, 2023.
  • The stockholders approved Proposal One which amends the Company’s Certificate of Incorporation to increase the total number of authorized shares of Common Stock to 750,000,000 shares.
  • Proposal One, which required an affirmative vote of a majority of the outstanding common stock for passage, received 71,844,322 share votes in favor of the proposal which represents 50.55% of the total shares outstanding.
  • The passage of Proposal One allows the Company to proceed with the proposed merger with Viewpoint Molecular Targeting, Inc.

Isoray Announces Adjournment of Annual Meeting of Stockholders to January 27, 2023

Retrieved on: 
Thursday, January 12, 2023
ISR, IsoRay, 2015 Michigan Proposal 1, Common stock, Institutional Shareholder Services, NYSE, Telephone, Health, Glass, Holding company, Shareholder

The Board of Directors, as well as leading proxy advisory firms Institutional Shareholder Services (“ISS”) and Glass, Lewis & Co., recommend stockholders vote in support of Proposal 1.

Key Points: 
  • The Board of Directors, as well as leading proxy advisory firms Institutional Shareholder Services (“ISS”) and Glass, Lewis & Co., recommend stockholders vote in support of Proposal 1.
  • Stockholders’ votes are very important and are critical for Isoray to move forward with the pending proposed merger with Viewpoint Molecular Targeting.
  • Management believes that the pending proposed merger represents a transformational opportunity for Isoray and all its stockholders.
  • Stockholders as of the October 20, 2022 record date can vote, even if they have subsequently sold their shares.

AMENDED: Isoray Announces Adjournment of Annual Meeting of Stockholders to January 12, 2023

Retrieved on: 
Wednesday, December 14, 2022
ISR, ISS, Seed, IsoRay, NYSE, Health, Institutional Shareholder Services, Certificate, News, Telephone, Annual general meeting, 2015 Michigan Proposal 1, PSLRA, Common stock, Glass, Cancer, Holding company

Proposals 2 and 3 have already been approved and approval of these two proposals was also required to consummate the merger.

Key Points: 
  • Proposals 2 and 3 have already been approved and approval of these two proposals was also required to consummate the merger.
  • Stockholders' votes are very important and are critical for Isoray to move forward with the pending proposed merger with Viewpoint Molecular Targeting.
  • Management believes that the pending proposed merger represents a transformational opportunity for Isoray and all its stockholders.
  • Isoray, Inc., through its subsidiary, Isoray Medical, Inc., is the sole producer of Cesium-131 brachytherapy seeds.

Isoray Announces Adjournment of Annual Meeting of Stockholders to January 12, 2022

Retrieved on: 
Wednesday, December 14, 2022
ISR, Seed, IsoRay, NYSE, Health, Institutional Shareholder Services, News, Telephone, Annual general meeting, 2015 Michigan Proposal 1, PSLRA, Common stock, Glass, Cancer, Holding company

Proposals 2 and 3 have already been approved and approval of these two proposals was also required to consummate the merger.

Key Points: 
  • Proposals 2 and 3 have already been approved and approval of these two proposals was also required to consummate the merger.
  • Stockholders’ votes are very important and are critical for Isoray to move forward with the pending proposed merger with Viewpoint Molecular Targeting.
  • Management believes that the pending proposed merger represents a transformational opportunity for Isoray and all its stockholders.
  • Stockholders as of the October 20, 2022 record date can vote, even if they have subsequently sold their shares.

ISORAY INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Isoray, Inc - ISR

Retrieved on: 
Saturday, November 12, 2022
Class Action Lawsuit, Professional Services, Legal, Viewpoint, Sale, LLC, KSF, ISR, NYSE, IsoRay

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq.

Key Points: 
  • Former Attorney General of Louisiana Charles C. Foti, Jr., Esq.
  • and the law firm of Kahn Swick & Foti, LLC (KSF) are investigating the proposed merger of Isoray, Inc (the Company) (NYSE: ISR) with Viewpoint Molecular Targeting, Inc. pursuant to which Viewpoint shareholders will end up owning 49% of the fully diluted outstanding capital stock of Isoray.
  • KSF is seeking to determine whether the merger and the process that led to it are adequate and fair to the Companys shareholders.
  • To learn more about KSF, whose partners include the Former Louisiana Attorney General, visit www.ksfcounsel.com .

Isoray Announces First Quarter Fiscal 2023 Financial Results and Provides Update to Pending Merger

Retrieved on: 
Thursday, November 10, 2022
GLOBE, Hospital, Private Securities Litigation Reform Act, Intellectual property, Marketing, Investment, NYSE, ISR, Seed, IsoRay, Webcast, Research, Travel, Health, Total, COVID-19, Cancer, SEC, ISO, News, Compliance, Brain, Time, D, Physician, Patient, Growth, D&O, PSLRA, FDA, Video game, Pharmaceutical industry

Isoray CEO Lori Woods said the pending merger signifies a watershed moment in the evolution of the company.

Key Points: 
  • Isoray CEO Lori Woods said the pending merger signifies a watershed moment in the evolution of the company.
  • The pending merger represents an exciting transformational opportunity for Isoray and all our stakeholders.
  • Revenue for the first quarter of fiscal 2023 decreased 33% to $1.72 million versus $2.56 million in the prior year comparable period.
  • Prostate brachytherapy represented 68% of total revenue for the first quarter of fiscal 2023 compared to 77% in the prior year comparable period.

Isoray To Announce First Quarter Fiscal 2023 Financial Results on November 10, 2022

Retrieved on: 
Monday, October 31, 2022
ISR, Webcast, Seed, IsoRay, Company, Cancer, GLOBE, NYSE

The Company will issue a press release announcing its financial results for the first quarter fiscal year 2023 after the close of the U.S. stock markets on November 10, 2022.

Key Points: 
  • The Company will issue a press release announcing its financial results for the first quarter fiscal year 2023 after the close of the U.S. stock markets on November 10, 2022.
  • Isoray, Inc. is a medical technology company pioneering advanced treatment applications and devices to deliver targeted internal radiation treatments for cancers throughout the body.
  • Isoray, Inc., through its subsidiary, Isoray Medical, Inc., is the sole producer of Cesium-131 brachytherapy seeds.
  • Learn more about this innovative Richland, Washington company and explore the many benefits and uses of Cesium-131 by visiting www.isoray.com .

Isoray Medical, Inc. and Viewpoint Molecular Targeting, Inc. Announce Investor Webcast on October 19, 2022 at 4:15 p.m. EDT

Retrieved on: 
Tuesday, October 18, 2022
Biotechnology, Radiology, Pharmaceutical, Health, LinkedIn, Mallinckrodt Institute of Radiology, Time, U.S. Securities and Exchange Commission, Private Securities Litigation Reform Act, Therapy, European Association of Nuclear Medicine, Review, Neoplasm, Neuroendocrine tumor, NYSE, Wilms' tumor, Seed, Twitter, Security (finance), Radiology, Multimedia, Viewpoint, Washington University in St. Louis, 8-K, Doctor of Philosophy, Association, Nuclear medicine, ISR, Toxicity, EDT, Clinical trial, European Association of Urology, Forward-looking statement, Peptide, Cancer, Medical imaging, IsoRay

Isoray, Inc., through its subsidiary, Isoray Medical, Inc., is the sole producer of Cesium-131 brachytherapy seeds.

Key Points: 
  • Isoray, Inc., through its subsidiary, Isoray Medical, Inc., is the sole producer of Cesium-131 brachytherapy seeds.
  • Learn more about this innovative Richland, Washington company and explore the many benefits and uses of Cesium-131 by visiting www.isoray.com .
  • Viewpoint Molecular Targeting is a radiopharmaceutical company developing precision oncology therapeutics and complementary diagnostic imaging agents.
  • These forward-looking statements (except as may be otherwise noted) speak only as of the date of this press release.